<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>药渡 | wechat-feeds</title><link>http://MzA5MjEzODQ3NA.favicon.privacyhide.com/favicon.ico</link><description>药渡以自有药物大数据为依托，对上市及临床在研药物、药物研究进展和重要药物市场商业动态作出信息整合分析，传递药物创新一手资讯</description><managingEditor> (hellodword)</managingEditor><pubDate>Thu, 25 Feb 2021 12:07:42 +0800</pubDate><image><url>http://MzA5MjEzODQ3NA.favicon.privacyhide.com/favicon.ico</url><title>药渡 | wechat-feeds</title><link>http://MzA5MjEzODQ3NA.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>优势片段杂交策略在药物研发中的应用</title><link>https://mp.weixin.qq.com/s/ZhgYunCBSsLAj5ovI6qZgQ</link><description></description><content:encoded><![CDATA[优势片段杂交策略在药物研发中的应用]]></content:encoded><pubDate>Wed, 24 Feb 2021 18:09:14 +0800</pubDate></item><item><title>Cytiva赋能生物制药系列课程第2课：加速新型抗体药物开发策略</title><link>https://mp.weixin.qq.com/s/z8ty2fFDNReAgYojx6Y0iQ</link><description></description><content:encoded><![CDATA[Cytiva赋能生物制药系列课程第2课：加速新型抗体药物开发策略]]></content:encoded><pubDate>Wed, 24 Feb 2021 18:09:14 +0800</pubDate></item><item><title>新药频出，胆管癌靶向药Futibatinib控制率超80%，前景光明</title><link>https://mp.weixin.qq.com/s/94UJ8xWXgF8woIg6CZPPqw</link><description></description><content:encoded><![CDATA[新药频出，胆管癌靶向药Futibatinib控制率超80%，前景光明]]></content:encoded><pubDate>Wed, 24 Feb 2021 18:09:14 +0800</pubDate></item><item><title>议程公开|60+生物药企领袖聚首申城，研发动态、成果展示、合作案例，你想了解的单抗/双抗/ADC热点尽在BIT 2021！</title><link>https://mp.weixin.qq.com/s/rLYYSkqmqc0Fa1BOtobPFg</link><description></description><content:encoded><![CDATA[议程公开|60+生物药企领袖聚首申城，研发动态、成果展示、合作案例，你想了解的单抗/双抗/ADC热点尽在BIT 2021！]]></content:encoded><pubDate>Wed, 24 Feb 2021 18:09:14 +0800</pubDate></item><item><title>好书推荐 | 药明康德经典译丛：有机人名反应——机理及合成应用（原书第五版）</title><link>https://mp.weixin.qq.com/s/0sPJJMEbBUYGs4qFuSV48g</link><description></description><content:encoded><![CDATA[好书推荐 | 药明康德经典译丛：有机人名反应——机理及合成应用（原书第五版）]]></content:encoded><pubDate>Wed, 24 Feb 2021 18:09:14 +0800</pubDate></item><item><title>药渡招聘 | 咨询合伙人</title><link>https://mp.weixin.qq.com/s/Jd5dxId10fd4sHtomxRMBw</link><description></description><content:encoded><![CDATA[药渡招聘 | 咨询合伙人]]></content:encoded><pubDate>Wed, 24 Feb 2021 18:09:14 +0800</pubDate></item><item><title>创新药的研发——靶点筛选及研发平台的搭建是关键</title><link>https://mp.weixin.qq.com/s/X-pWHwnQIlWSmpzspz7ndw</link><description></description><content:encoded><![CDATA[创新药的研发——靶点筛选及研发平台的搭建是关键]]></content:encoded><pubDate>Tue, 23 Feb 2021 18:10:05 +0800</pubDate></item><item><title>药物分子筛选新技术荟萃</title><link>https://mp.weixin.qq.com/s/rhmzhMXvM2ONCNlFA6QzAQ</link><description></description><content:encoded><![CDATA[药物分子筛选新技术荟萃]]></content:encoded><pubDate>Tue, 23 Feb 2021 18:10:05 +0800</pubDate></item><item><title>汇总 | 新型药物靶标集锦</title><link>https://mp.weixin.qq.com/s/x1mEuiiUqW0WS7AVyKj2xw</link><description></description><content:encoded><![CDATA[汇总 | 新型药物靶标集锦]]></content:encoded><pubDate>Tue, 23 Feb 2021 18:10:05 +0800</pubDate></item><item><title>培优5周年庆典系列活动《2021医药行业发展展望与战略突破研讨峰会》</title><link>https://mp.weixin.qq.com/s/NR2FFmWQkqM1Mt1iy51wIQ</link><description></description><content:encoded><![CDATA[培优5周年庆典系列活动《2021医药行业发展展望与战略突破研讨峰会》]]></content:encoded><pubDate>Tue, 23 Feb 2021 18:10:05 +0800</pubDate></item><item><title>好书推荐 | RNA疫苗方法与操作/王升启</title><link>https://mp.weixin.qq.com/s/CB8gX8oSOTOx-lmw9UT3RA</link><description></description><content:encoded><![CDATA[好书推荐 | RNA疫苗方法与操作/王升启]]></content:encoded><pubDate>Tue, 23 Feb 2021 18:10:05 +0800</pubDate></item><item><title>药渡招聘 | 咨询师</title><link>https://mp.weixin.qq.com/s/JewVFMLsrXF0MU_NpeQhIQ</link><description></description><content:encoded><![CDATA[药渡招聘 | 咨询师]]></content:encoded><pubDate>Tue, 23 Feb 2021 18:10:05 +0800</pubDate></item><item><title>简述：药物开发过程中的杂质研究与控制</title><link>https://mp.weixin.qq.com/s/enEmvRv6GFi28vCZRb4EMg</link><description></description><content:encoded><![CDATA[简述：药物开发过程中的杂质研究与控制]]></content:encoded><pubDate>Tue, 23 Feb 2021 09:05:30 +0800</pubDate></item><item><title>【网络研讨会】专家解读RWD和RWE在药审中的应用</title><link>https://mp.weixin.qq.com/s/fPzbgAU04dFf4Y8m-jfxMw</link><description></description><content:encoded><![CDATA[【网络研讨会】专家解读RWD和RWE在药审中的应用]]></content:encoded><pubDate>Tue, 23 Feb 2021 09:05:30 +0800</pubDate></item><item><title>从小众到大众——通用CAR-T未来已来</title><link>https://mp.weixin.qq.com/s/TjJNcD0H6gFAvAA_aPyUOA</link><description></description><content:encoded><![CDATA[从小众到大众——通用CAR-T未来已来]]></content:encoded><pubDate>Tue, 23 Feb 2021 09:05:30 +0800</pubDate></item><item><title>汇恩兰德为您提供全方位的滴眼剂CDMO服务！</title><link>https://mp.weixin.qq.com/s/KF4m8P3m3ZugGSTzfEO9AA</link><description></description><content:encoded><![CDATA[汇恩兰德为您提供全方位的滴眼剂CDMO服务！]]></content:encoded><pubDate>Tue, 23 Feb 2021 09:05:30 +0800</pubDate></item><item><title>好书推荐 |《药物设计：方法、概念和作用模式》</title><link>https://mp.weixin.qq.com/s/YxXJA3RZCfwkNnPO4KhJOQ</link><description></description><content:encoded><![CDATA[好书推荐 |《药物设计：方法、概念和作用模式》]]></content:encoded><pubDate>Tue, 23 Feb 2021 09:05:30 +0800</pubDate></item><item><title>药渡招聘 | 药学分析师</title><link>https://mp.weixin.qq.com/s/lK5eXNI7g1cRWnyFMT7Nkg</link><description></description><content:encoded><![CDATA[药渡招聘 | 药学分析师]]></content:encoded><pubDate>Tue, 23 Feb 2021 09:05:30 +0800</pubDate></item><item><title>一文初识：命运多舛的马兜铃酸！</title><link>https://mp.weixin.qq.com/s/BTuCgMQn-u4UEHQudD1A9w</link><description></description><content:encoded><![CDATA[一文初识：命运多舛的马兜铃酸！]]></content:encoded><pubDate>Sun, 21 Feb 2021 23:58:14 +0800</pubDate></item><item><title>安进终止三款双抗产品临床试验，双抗管线抱定CD3不放松</title><link>https://mp.weixin.qq.com/s/8bVKpiNub-dw7q8Ge-PpoQ</link><description></description><content:encoded><![CDATA[安进终止三款双抗产品临床试验，双抗管线抱定CD3不放松]]></content:encoded><pubDate>Sun, 21 Feb 2021 23:58:14 +0800</pubDate></item></channel></rss>